Hitoshi Ojima

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet · 2016 · 1.1K citations

Surgical Oncology, Oncology, Pancreatic Cancer +6

Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma

Hiroyuki Kato, Hiroyuki Kuwano, Masanobu Nakajima et al. · Cancer · 2002 · 298 citations

The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma

Hiroyuki Kato, Tatsuya Miyazaki, Masanobu Nakajima et al. · Cancer · 2004 · 241 citations · Full text

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer

Jun Watanabe, Kei Muro, Kohei Shitara et al. · JAMA · 2023 · 222 citations · Full text

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial

Yukihide Kanemitsu, Kohei Shitara, Junki Mizusawa et al. · Journal of Clinical Oncology · 2021 · 187 citations · Full text